These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20628209)

  • 21. Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant.
    Yu YZ; Wang S; Bai JY; Zhao M; Chen A; Wang WB; Chang Q; Liu S; Qiu WY; Pang XB; Xu Q; Sun ZW
    Clin Immunol; 2013 Oct; 149(1):11-24. PubMed ID: 23886550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
    van Dyck CH
    Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alzheimer disease: Lessons from immunotherapy for Alzheimer disease.
    Wang YJ
    Nat Rev Neurol; 2014 Apr; 10(4):188-9. PubMed ID: 24638135
    [No Abstract]   [Full Text] [Related]  

  • 24. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
    Solomon B
    Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of therapies of Alzheimer's disease].
    Shoji M
    Nihon Ronen Igakkai Zasshi; 2003 Sep; 40(5):473-5. PubMed ID: 14579716
    [No Abstract]   [Full Text] [Related]  

  • 27. [Immunotherapy for Alzheimer's disease targeting Aβ].
    Tabira T
    Nihon Rinsho; 2016 Mar; 74(3):423-6. PubMed ID: 27025080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunotherapy targeting on Abeta for Alzheimer disease].
    Tabira T
    Nihon Rinsho; 2011 Dec; 69 Suppl 10 Pt 2():77-82. PubMed ID: 22755159
    [No Abstract]   [Full Text] [Related]  

  • 29. [Antibody therapy for Alzheimer's disease].
    Tabira T; Matsumoto SE; Jin H
    Rinsho Shinkeigaku; 2011 Nov; 51(11):1160-1. PubMed ID: 22277519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Passive Aβ Immunotherapy: Current Achievements and Future Perspectives.
    Schilling S; Rahfeld JU; Lues I; Lemere CA
    Molecules; 2018 May; 23(5):. PubMed ID: 29751505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.
    Liu J; Yang B; Ke J; Li W; Suen WC
    Drugs Aging; 2016 Oct; 33(10):685-697. PubMed ID: 27699633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current progress in beta-amyloid immunotherapy.
    Schenk D; Hagen M; Seubert P
    Curr Opin Immunol; 2004 Oct; 16(5):599-606. PubMed ID: 15342006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
    Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
    ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genentech's Alzheimer's antibody trial to study disease prevention.
    Garber K
    Nat Biotechnol; 2012 Aug; 30(8):731-2. PubMed ID: 22871696
    [No Abstract]   [Full Text] [Related]  

  • 36. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I.
    Agadjanyan MG; Cribbs DH
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):1-6. PubMed ID: 19275632
    [No Abstract]   [Full Text] [Related]  

  • 37. Generation and brain delivery of anti-aggregating antibodies against beta-amyloid plaques using phage display technology.
    Solomon B; Frenkel D
    J Neural Transm Suppl; 2002; (62):321-5. PubMed ID: 12456075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved synaptic and cognitive function in aged 3 × Tg-AD mice with reduced amyloid-β after immunotherapy with a novel recombinant 6Aβ15-TF chimeric vaccine.
    Yu YZ; Li QL; Wang HC; Liu S; Pang XB; Xu Q; Zhou XW; Huang PT
    Clin Immunol; 2018 Aug; 193():12-23. PubMed ID: 29803820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine.
    Yu YZ; Xu Q
    Hum Vaccin Immunother; 2016 Nov; 12(11):2801-2804. PubMed ID: 27379885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!
    Lee HG; Zhu X; Nunomura A; Perry G; Smith MA
    Am J Pathol; 2006 Sep; 169(3):738-9. PubMed ID: 16936250
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.